antibody-analytics-logo.svg

Capabilities

Our Expertise

Services

Target discovery

Drug Classes

Cooperation

Testimonials

Lead Selection

Lead Optimisation & Characterisation

Our Service Models

Strategic partnerships

Our Equipment

Product Characterisation

Our Team

Biosimilar Characterisation

Careers

News

Contact Us

gavin small

Antibody Analytics | Immuno-Oncology Webinar with SelectScience

<div class="raw-html-embed"><div class="center"><iframe width="560" height="315" src="https://www.youtube.com/embed/aooi0DLoGe8?si=pXDkLxv9vKDaxYC0" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen=""></iframe></div></div>Our next immuno-oncology webinar with SelectScience is now available to stream on demand!&nbsp;Immuno-oncology is undergoing profound changes. Thousands of new treatments are being developed within the global drug discovery pipeline. With this rise in new therapeutics comes a need for robust in vitro assays to accurately characterise their mechanisms of action and effector functions.&nbsp;Our Senior Study Manager Dr Gavin Meehan stars in the latest collaboration between Antibody Analytics and <a target="_blank" rel="noopener noreferrer" href="https://www.selectscience.net/">SelectScience</a>. The webinar discusses the different in vitro assays currently used in immuno-oncology drug discovery, as well as the new types of assays in development.&nbsp;<h2 style="text-align:justify;">Key takeaways include:</h2><ul style="list-style-type:disc;"><li>The various cell-type-specific assays available for characterising different immunotherapies</li><li>How inducible cell lines can help to better understand the binding capabilities of therapeutics</li><li>How the transition to more complex systems like tissue organoids can provide more robust characterisation data</li></ul><h2 style="text-align:justify;">IndEx-2: Dual inducible&nbsp;in vitro cell line system</h2>In addition, Gavin explores our <a target="_blank" rel="noopener noreferrer" href="https://cld.antibodyanalytics.com/index-2">IndEx-2</a> dual inducible in vitro cell line system and how it can be used in combination with our primary cell platforms to determine thresholds of activation. He delves into the potential of ‘on-target/off-tumour’ effects for antibody-targeted therapeutic candidates.The webinar also features a Q&amp;A portion and questions the future necessity of using animal models in drug discovery.&nbsp;Are you working in immuno-oncology and interested in our in vitro assay <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/capabilities">capabilities</a>?&nbsp;<div class="raw-html-embed"><div class="center"><a href="https://meetings.hubspot.com/cmiller71" target="_blank" class="external-btn-primary">Speak to a scientist</a></div>
</div>

webinar

Our next immuno-oncology webinar with SelectScience is now available to stream on demand!

Leveraging human primary cell in vitro assays to advance immune targeted cancer therapeutics | Webinar

Michahaila Downie.jpeg

Celebrating Discovery Week at Antibody Analytics

The last week of May marks Antibody Analytics’ Discovery Week! This is the third year we’ve commemorated the <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/antibody-analytics-opens-discovery-centre">opening of our Discovery Centre</a>. It's also a chance for us to recognise our achievements as a team and in the wider industry.<h2>The Discovery Centre’s expansion: Shiny new labs and vibrant office space</h2>Antibody Analytics is growing, literally! Following our&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/antibody-analytics-secures-multi-million-pound-investment">multi-million-pound investment from NorthEdge</a>, we’re expanding our state-of-the-art facilities. The 560 square meter development will allow for bigger lab space as well as a contemporary office.&nbsp;<img class="image_resized" style="width:50%;" src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/DSC_05015_a55c9e4c21.JPG" alt="DSC05015.JPG" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_DSC_05015_a55c9e4c21.JPG 245w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_DSC_05015_a55c9e4c21.JPG 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_DSC_05015_a55c9e4c21.JPG 750w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_DSC_05015_a55c9e4c21.JPG 1000w," sizes="100vw"><img class="image_resized" style="width:50%;" src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/DSC_05099_9887e8d7cb.JPG" alt="DSC05099.JPG" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_DSC_05099_9887e8d7cb.JPG 245w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_DSC_05099_9887e8d7cb.JPG 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_DSC_05099_9887e8d7cb.JPG 750w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_DSC_05099_9887e8d7cb.JPG 1000w," sizes="100vw"><img class="image_resized" style="width:50%;" src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/DSC_05060_5fb88270cc.JPG" alt="DSC05060.JPG" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_DSC_05060_5fb88270cc.JPG 245w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_DSC_05060_5fb88270cc.JPG 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_DSC_05060_5fb88270cc.JPG 750w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_DSC_05060_5fb88270cc.JPG 1000w," sizes="100vw"><img class="image_resized" style="width:50%;" src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/DSC_05082_b9b29b1cdc.JPG" alt="DSC05082.JPG" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_DSC_05082_b9b29b1cdc.JPG 245w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_DSC_05082_b9b29b1cdc.JPG 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_DSC_05082_b9b29b1cdc.JPG 750w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_DSC_05082_b9b29b1cdc.JPG 1000w," sizes="100vw"><h2>From a spark of an idea to a groundbreaking innovation: The reception of IndEx-2</h2>2023 saw the launch of our trademark technology,&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://cld.antibodyanalytics.com/index-2">IndEx-2</a>. This has proven to be an incredible tool in drug discovery and has been well-received by our clients and the wider industry.<blockquote>When we conceived of IndEx-2, it was to create a solution for the modelling of on target, off tumour effects in vitro. This was a real world challenge that I had first hand experience of in CAR-T cell therapy development.&nbsp;We have been enthused by the response of antibody-targeted developers to IndEx-2. We knew that IndEx-2 would have broad utility, and the feedback from the industry provides further validation that we are tackling the problems that matter.Dr Adele Hannigan, Chief Business Officer.&nbsp;</blockquote>The rapidly customisable in vitro&nbsp;cell line platform can determine antigen density activation thresholds of targeted candidate immunotherapies. More importantly, it does so in a cost-effective manner early in the drug development process.&nbsp;The technology can be applied to an array of antibody-targeted therapies; CAR-engineered cell therapies, bispecific antibodies, multispecifics, immune cell engagers, monoclonal antibodies,&nbsp;ADCs and more.&nbsp;While the number of antibody-targeted I-O therapeutics in development is growing, there is a lack of in vitro systems to test their safety and efficacy. IndEx-2 addresses this challenge. Notably, we are the only service provider with <a target="_blank" rel="noopener noreferrer" href="https://cld.antibodyanalytics.com/index-2">IndEx-2</a> technology.<h2 style="text-align:justify;">Shining like a star: Events, partnerships, and awards</h2>This year, Antibody Analytics has gone global. We’ve attended more than 13&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/">conferences</a>, from Boston to Basel. Conferences allow us to connect with fellow thought-leaders in the immunology space, as well as showcase our <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/capabilities">research capabilities</a>.&nbsp;<img class="image_resized" style="width:50%;" src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/D15_A7_FC_4_CA_10_4121_9_B9_D_DCF_0_EE_8_DA_75_B_67b2b8048a.jpeg" alt="D15A7FC4-CA10-4121-9B9D-DCF0EE8DA75B.jpeg" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_D15_A7_FC_4_CA_10_4121_9_B9_D_DCF_0_EE_8_DA_75_B_67b2b8048a.jpeg 208w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_D15_A7_FC_4_CA_10_4121_9_B9_D_DCF_0_EE_8_DA_75_B_67b2b8048a.jpeg 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_D15_A7_FC_4_CA_10_4121_9_B9_D_DCF_0_EE_8_DA_75_B_67b2b8048a.jpeg 750w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_D15_A7_FC_4_CA_10_4121_9_B9_D_DCF_0_EE_8_DA_75_B_67b2b8048a.jpeg 1000w," sizes="100vw"><img class="image_resized" style="width:50%;" src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/B5_C84_F50_2426_473_D_A4_A5_7_DDB_8_CD_2245_B_06bd0a7858.jpeg" alt="B5C84F50-2426-473D-A4A5-7DDB8CD2245B.jpeg" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_B5_C84_F50_2426_473_D_A4_A5_7_DDB_8_CD_2245_B_06bd0a7858.jpeg 208w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_B5_C84_F50_2426_473_D_A4_A5_7_DDB_8_CD_2245_B_06bd0a7858.jpeg 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_B5_C84_F50_2426_473_D_A4_A5_7_DDB_8_CD_2245_B_06bd0a7858.jpeg 750w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_B5_C84_F50_2426_473_D_A4_A5_7_DDB_8_CD_2245_B_06bd0a7858.jpeg 1000w," sizes="100vw">We also enjoyed attending the&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/antibody-analytics-business-leadership-award">Scottish Life Science Awards</a> dinner (see above), as finalists in the Business Leadership category.&nbsp;Along with Agilent Technologies, our CSO Dr Agapitos Patakas (below) won&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/antibody-analytics-wins-select-science-webinar-of-the-year">SelectScience’s Webinar of the Year Award</a> for his presentation of our in vitro T cell exhaustion model.&nbsp;<figure class="image image_resized" style="width:50%;"><img src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/Agi_award_0263eab3ea.jpg" alt="Agi award.jpg" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_Agi_award_0263eab3ea.jpg 209w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_Agi_award_0263eab3ea.jpg 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_Agi_award_0263eab3ea.jpg 750w," sizes="100vw"></figure>We expanded our capabilities into the third dimension with our&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/antibody-analytics-and-screen-in3-d-strike-up-strategic-partnership">ScreenIn3D</a> Strategic Partnership, as well as took practical steps towards inclusivity by partnering with&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/antibody-analytics-proud-to-partner-with-black-professionals-scotland">Black Professionals Scotland</a>.It’s been a remarkable 12 months since our last Discovery Week and looking back at all these achievements we couldn’t be happier. It’s rewarding to help our clients’ potentially life-saving therapies get closer to patients.&nbsp;Cheers to Discovery Week and to many more years of success ahead!

discovery week

Discovery week

We're looking back at the opening of our Discovery Centre and our team's achievements so far. 

Andrew

Antibody Analytics | The Successful Development of a Potency Bioassay Research Poster

<h2 style="margin-left:0px;text-align:justify;">What are potency bioassays?</h2>The quantitative measurement of potency plays a critical role in biopharmaceutical development. <a target="_blank" rel="noopener noreferrer" href="https://www.canva.com/design/DAFUj0KjblY/YpCUFvbklfTzdqNqNqoijQ/edit?utm_content=DAFUj0KjblY&amp;utm_campaign=designshare&amp;utm_medium=link2&amp;utm_source=sharebutton">Potency bioassays</a> are essential tools for the measurement of potency. However, the complexity of measuring a meaningful biological response representative of the biotherapeutics' mechanism of action can pose significant challenges.&nbsp;Along with <a target="_blank" rel="noopener noreferrer" href="https://www.tanvex.com/index.php">Tanvex Biopharma</a>, we have applied a novel approach using the real-time kinetic capabilities of <a target="_blank" rel="noopener noreferrer" href="https://www.agilent.com/en/product/cell-analysis/xcelligence-system">xCELLigence</a>. This de-risks assay development for an inhibition of proliferation assay for an anti-HER2 monoclonal antibody.&nbsp;Read more in our poster ‘Real-time kinetic data in the successful development of an inhibition of proliferation potency bioassay'.<div class="raw-html-embed"><div class="center"><a href="https://8176205.fs1.hubspotusercontent-na1.net/hubfs/8176205/Research%20posters/FOB%20&amp;%20PEGS%20-%20BioA%20poster%20-%20AA%20&amp;%20Tanvex%20%7C%20Real-time%20kinetic%20data%20in%20the%20successful%20development%20of%20an%20inhibition%20of%20proliferation%20potency%20bioassay.pdf" target="_blank" class="external-btn-primary">Download now</a></div></div><h2 style="text-align:justify;">Producing an anti-proliferation potency bioassay</h2>Bioassay development followed these steps:<ul><li style="text-align:justify;">Inhibition of proliferation assay principle and the potential risks for assay performance&nbsp;</li><li style="text-align:justify;">Application of real-time kinetic proliferation data in development&nbsp;</li><li style="text-align:justify;">Transfer of assay parameters to a CMC-friendly assay format&nbsp;</li><li style="text-align:justify;">Inhibition of proliferation assay qualification&nbsp;</li></ul><figure class="image"><a href="https://8176205.fs1.hubspotusercontent-na1.net/hubfs/8176205/Research%20posters/FOB%20&amp;%20PEGS%20-%20BioA%20poster%20-%20AA%20&amp;%20Tanvex%20%7C%20Real-time%20kinetic%20data%20in%20the%20successful%20development%20of%20an%20inhibition%20of%20proliferation%20potency%20bioassay.pdf" target="_blank" rel="noopener noreferrer"><img src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/potency_poster_download_7ab6993282.png" alt="potency poster download.png" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_potency_poster_download_7ab6993282.png 125w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_potency_poster_download_7ab6993282.png 401w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_potency_poster_download_7ab6993282.png 601w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_potency_poster_download_7ab6993282.png 802w," sizes="100vw"></a></figure>We have successfully demonstrated the applicability of real-time kinetic data in the development of an anti-proliferation potency bioassay. The assay demonstrates reliable performance over time and is unaffected by different SK-BR-3 passage numbers, different operators, or different FBS lots.&nbsp;It provides a detailed understanding of the effects of assay conditions on cellular responses, to produce a reliable bioassay with consistent performance. This is important for the development of proliferation bioassays for process development, characterisation, stability, and biosimilar similarity assessments. &nbsp;Have any questions about our inhibition of proliferation potency bioassay?&nbsp;<div class="raw-html-embed"><div class="center"><a href="https://meetings.hubspot.com/cmiller71" target="_blank" class="external-btn-primary">Speak to a scientist </a></div></div>

potency 

Using real-time kinetic data to develop a potency bioassay.

Development of an Inhibition of Proliferation Potency Bioassay | Research Poster

Blog Author img (3).png

Antibody Analytics | Effective IgG1 Fc Silencing

<h2 style="text-align:justify;">What is Fc silencing?&nbsp;</h2>Monoclonal antibodies (mAbs) are pivotal in mediating effector functions. They do this by engaging with Fc gamma receptors on immune cells and initiating the complement cascade via their Fc domains.&nbsp;For therapeutic applications where effector function is undesirable, a range of Fc ‘silencing’ techniques have been developed&nbsp;to mitigate or nullify complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity&nbsp;(ADCC) responses. However, despite these efforts, residual binding and functional activity are often still detectable.&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://mabsolve.com/">mAbsolve</a>’s innovation, the STR mutation, marks a significant advancement in Fc silencing. It demonstrates complete cessation of Fc binding and functional activities. Using Antibody Analytics’ advanced primary cell and <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/watch-our-spr-reflections-video-series">SPR platforms</a>, we can rigorously assess antibody constructs to ensure effective silencing. This sets a new standard in the development of safer therapeutic antibodies.&nbsp;Read our poster, led by Senior Study Manager Fiona Miller, ‘Effective IgG1 Fc silencing: characterisation of residual binding and functional activity’.&nbsp;<div class="raw-html-embed"><div class="center"><a href="https://8176205.fs1.hubspotusercontent-na1.net/hubfs/8176205/Research%20posters/Fionas%20Effector%20Function%20Poster%20final%20draft%20%7C%20FOB%202024.pdf" target="_blank" class="external-btn-primary"> Read now </a></div></div><h2>The benefits of Antibody Analytics’ approach&nbsp;</h2><ul><li style="text-align:justify;">Standard assay designs greatly reduce time spent in optimisation</li><li style="text-align:justify;">Control of donor material and Fc receptor stocks</li><li style="text-align:justify;">Methods are highly sensitive and physiologically relevant</li><li style="text-align:justify;">Target cell line development in-house&nbsp;</li><li style="text-align:justify;">Low sample volume requirements</li></ul><figure class="image image_resized" style="width:50%;"><img src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/fiona_download_poster_9469e57804.png" alt="fiona download poster.png" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_fiona_download_poster_9469e57804.png 131w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_fiona_download_poster_9469e57804.png 418w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_fiona_download_poster_9469e57804.png 628w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_fiona_download_poster_9469e57804.png 837w," sizes="100vw"></figure>From SPR binding assays and primary cell functional assays, our data conclusively shows that neither employing IgG2 and IgG4 isotypes, nor the LALA mutation completely silences Fc binding and function.&nbsp;Only the STR mutation achieves complete Fc silencing. As the SPR and bioassay data demonstrates, it is necessary to conduct both binding and primary cell functional assays to fully characterize Fc activity, as well as understand the implications of any lingering activity.&nbsp;Have any questions about confirmation of Fc silencing?&nbsp;<div class="raw-html-embed"><div class="center"><a href="https://meetings.hubspot.com/cmiller71" target="_blank" class="external-btn-primary"> Speak to a scientist </a></div>

</div>

Fc silencing 

Effective IgG1 Fc silencing: characterisation of residual binding and functional activity.

Effective IgG1 Fc Silencing | Research Poster

<h2>The&nbsp; Collaborative&nbsp; immunology CRO</h2>Enriching your team

home page carousel_cells_1.png

The Collaborative Immunology CRO

Antibody Analytics

<h2>The&nbsp; Creative&nbsp; immunology CRO</h2>Your challenge is our muse

home page carousel_creative_2.png

The Creative Immunology CRO

<h2>The&nbsp; Consultative&nbsp; immunology CRO</h2>Sharing our solutions

home page carousel_fur ball_3.png

The Consultative Immunology CRO

Antibody Analytics Ltd.&nbsp;VAT Number: GB 235 2396 11 | Registered in Scotland

<h1>Our new transformational IndEx-2 system has launched</h1>A powerful, inducible cell system that allows selection of the safest and most efficacious targeted therapies. IndEx-2 is an in vitro cell-based platform that provides inducible expression of any target antigen of interest (TAOI).<ul><li>Safety: Gain information on the potential of “on target, off tumour effects” via precise control of TAOI expression to model physiological and pathological expression levels</li><li>Efficacy: Determine the antigen density activation threshold of targeted immunotherapies, including immune cell engagers, ADCs and engineered immune cell therapies</li></ul>IndEx-2 is an effective tool that can be used to enhance a pre-clinical data package with information that offers a more comprehensive understanding of a targeted drug mechanism of action and functional profile.&nbsp;&nbsp;<div class="raw-html-embed"><div class="left"><a href="https://cld.antibodyanalytics.com/index-2" target="_blank" class="external-btn-primary">Find out more</a></div></div>

IndEx2 Introducing IndEx2 Discover the New Solution for Measuring the Safety and Efficacy of Your Therapeutic -01.png

small_IndEx2 Introducing IndEx2 Discover the New Solution for Measuring the Safety and Efficacy of Your Therapeutic -01.png

thumbnail_IndEx2 Introducing IndEx2 Discover the New Solution for Measuring the Safety and Efficacy of Your Therapeutic -01.png

Antibody Analytics - The Collaborative Immunology CRO

<h1>Meet us in person at upcoming events</h1>We’re pleased to announce that in 2024 we’ll be exhibiting at the following prestigious conferences:&nbsp;<ul><li>BIO US in San Diego: 3-6 June</li><li>HubXchange in Boston: 17 June - Antibody Therapeutics Xchange</li><li>HubXchange in Boston: 18 June &nbsp;- I-O Xchange</li><li>Immuno-Oncology Summit US in Philadelphia: 7-9 August – Booth #3</li><li>Nordic Life Science Days in Malmo: 17-19 Sep 2024&nbsp;</li><li>Festival of Biologics Europe in Basel: 15-17 October&nbsp;</li><li>PEGS Europe in Barcelona: 5-7 Nov 2024</li><li>Society for Immunotherapy for Cancer (SITC) in Texas: 6-10 November – Booth #538</li></ul><div class="raw-html-embed"><div class="left"><a href="https://share.hsforms.com/1YIM97zfBTGOnauA5PZapog4v8st" target="_blank" class="external-btn-primary">Find a suitable time to talk</a></div></div>

Create

Consult

Collaborate

Meet us in person at upcoming events

Our new transformational IndEx-2 system has launched